Supplementary Figure 1. Efficacy of RAF1 knockdown

Human primary myometrial cells were transfected with or without 200 nM siRAF1 or siCONT for 48 h (n=5 patients). (A) RAF1 mRNA expression was analysed by qRT-PCR and the fold change was calculated relative to the siCONT transfected cells. Data is displayed as mean ± SEM. *P<0.05 vs. siCONT (one-sample t-test). (B) RAF1 protein expression was analysed by Western blot. Protein expression was normalised to ACTB and the fold change was calculated to the siCONT transfected cells. Data is displayed as mean ± SEM. *P<0.05 vs. siCONT transfected cells (Student’s t-test). Representative Western blot from 1 patient is also shown. (C) Cell viability was assessed using a MTT assay and the fold change was calculated relative to the siCONT transfected cells. Data is displayed as mean ± SEM. *P<0.05 vs. siCONT (one-sample t-test).